Case Reports : Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report = Case Reports : Treatment of Keratoacanthoma with 5% Imiquimod Cream and Review of the Previous Report

다국어 초록 (Multilingual Abstract)

Keratoacanthoma (KA) is a benign epidermal tumor, characterized by rapid and abundant growth, a tendency toward spontaneous regression and histopathologic similarity to squamous cell carcinoma (SCC). Because KA can be easily misdiagnosed as SCC, surgery is considered the treatment of choice. Recently, regression of KAs following application of 5% imiquimod cream (Aldara(R)) has been reported. We present 4 cases of KA treated with topical imiquimod, applied 3 to 4 times a week. Obvious improvement was observed after 4 to 6 weeks of application and the lesions were almost cleared leaving scars after 9 to 11 weeks. These results show that topical imiquimod can be an effective option for the conservative management of KA as previously reported. We also suggest that lesions treated with imiquimod cream should be considered for biopsy to judge histopathological remission after 5 to 8 weeks of application to shorten the duration of the treatment.

참고문헌 (Reference)

1 Ko NY, "Treatment of keratoacanthoma with 5% imiquimod cream" 18 : 14-17, 2006

2 Dendorfer M, "Topical treatment with imiquimod may induce regression of facial keratoacanthoma" 13 : 80-82, 2003

3 Calista D, "Topical imiquimod for the treatment of keratoacanthomas" 18 : 590-591, 2008

4 Di Lernia V, "Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream" 18 : 626-629, 2004

5 Yoshikawa K, "Relative amounts of keratin 17 are higher than those of keratin 16 in hair-folliclederived tumors in comparison with nonfollicular epithelial skin tumors" 104 : 396-400, 1995

6 Vergara A, "Multiple and relapsing keratoacanthomas developing at the edge of the skin grafts site after surgery and after radiotherapy" 33 : 994-996, 2007

7 Karaa A, "Keratoacanthoma: a tumor in search of a classification" 46 : 671-678, 2007

8 Schwartz RA, "Keratoacanthoma: a clinico-pathologic enigma" 30 : 326-333, 2004

9 Beham A, "Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma" 5 : 269-280, 1998

10 Griffiths RW, "Keratoacanthoma observed" 57 : 485-501, 2004

11 Yuge S, "Keratoacanthoma centrifugum marginatum: response to topical 5-fluorouracil" 54 (54): 218-219, 2006

12 Seifert A, "Keratoacanthoma and its clinical variants. Review of the literature and histopathologic analysis of 90 cases" 40 : 189-202, 1989

13 Annest NM, "Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature" 56 : 989-993, 2007

14 Paternò EJ, "Imiquimod for restoring local immunity in a renal transplant patient with persistent keratoacanthoma" 14 : 8-, 2008

15 Bhatia N, "Imiquimod as a possible treatment for keratoacanthoma" 3 : 71-74, 2004

16 김용주, "Imiquimod 5% 크림으로 치료한 각화극세포종 1예" 대한피부과학회 42 (42): 1321-1324, 2004

17 Kwittken J, "A histologic chronology of the clinical course of the keratocarcinoma (so-called keratoacanthoma)" 42 : 127-135, 1975